参考文献/References:
[1]Gintant G,Burridge P,Gepstein L,et al. Use of human induced pluripotent stem cell-derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing:a scientific statement from the American Heart Association[J]. Circ Res,2019,125(10):75-92.
[2]Khan MF,Gottesman S,Boyella R,et al. Gemcitabine-induced cardiomyopathy:a case report and review of the literature[J]. J Med Case Rep,2014,8:220.
[3]Ferrari D,Carbone C,Codecà C,et al. Gemcitabine and atrial fibrillation:a rare manifestation of chemotherapy toxicity[J]. Anticancer Drugs,2006,17(3):359-361.
[4]Tayer-Shifman OE,Rottenberg Y,Shuvy M. Gemcitabine-induced supraventricular tachycardia[J]. Tumori, 2009,95(4):547-549.
[5]Santini D,Tonini G,Abbate A,et al. Gemcitabine-induced atrial fibrillation:a hitherto unreported manifestation of drug toxicity[J]. Ann Oncol,2000,11(4):479-481.
[6]Ozturk B,Tacoy G,Coskun U,et al. Gemcitabine-induced acute coronary syndrome:a case report[J]. Med Princ Pract,2009,18(1):76-80.
[7]Bdair FM,Graham SP,Smith PF,et al. Gemcitabine and acute myocardial infarction—a case report[J]. Angiology, 2006,57(3):367-371.
[8]Kalapura T,Krishnamurthy M,Reddy CV. Acute myocardial infarction following gemcitabine therapy—a case report[J]. Angiology,1999,50(12):1021-1025.
[9]Tavil Y,Arslan U,Okyay K,et al. Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man[J]. Onkologie,2007,30(5):253-255.
[10]Ciotti R,Belotti G,Facchi E,et al. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine[J]. Ann Oncol,1999,10(8):997.
[11]Yajima T,Furukawa Y,Ishii Y,et al. Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years[J]. Gan To Kagaku Ryoho,2004,31(6):953-957.
[12]Storniolo AM,Allerheiligen SR,Pearce HL. Preclinical,pharmacologic,and phase Ⅰ studies of gemcitabine[J].Semin Oncol,1997,24(2 suppl 7):S7-2-S7-7.
[13]Sauer-Heilborn A,Kath R,Schneider CP,et al. Severe non-haematological toxicity after treatment with gemcitabine[J]. J Cancer Res Clin Oncol,1999,125(11):637-640.
[14]刘静,唐小丽,谭小辉. 1例吉西他滨过敏致呼吸心搏骤停病人的护理体会[J]. 全科护理,2010,8(12):3193.
[15]Alam S,Illo C,Ma YT,et al. Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series[J].Case Rep Oncol,2018,11(1):221-227.
[16]Montastruc G,Favreliere S,Sommet A,et al. Drugs and dilated cardiomyopathies:a case/noncase study in the French Pharmaco Vigilance Database[J]. Br J Clin Pharmacol,2010,69(3):287-294.
[17]Kat?c?a?#305 MT,Eken A. Gemcitabine-induced coronary vasospasm:a case report[J]. Turk Kardiyol Dern Ars,2017,45(2):172-175.
[18]Dasanu CA. Gemcitabine:vascular toxicity and prothrombotic potential[J]. Expert Opin Drug Saf, 2008,7(6):703-716.
[19]Frustaci A,Chimenti C,Bellocci F,et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation[J]. Circulation,1997,96(4):1180-1184.
[20]Bruchard M,Mignot G,Derangère V,et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth[J]. Nat Med,2013,19(1):57-64.
[21]叶倩伶,毛德文,王明刚,等. NOD样受体蛋白3炎性体在肝脏疾病发生发展中的作用[J]. 临床肝胆病杂志, 2019,35(10):2346-2350.
[22]Yao C,Veleva T,Scott Jr L,et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation[J]. Circulation,2018,138(20):2227-2242.
[23]Alexandre J,Moslehi JJ,Bersell KR,et al. Anticancer drug-induced cardiac rhythm disorders:current knowledge and basic underlying mechanisms[J]. Pharmacol Ther,2018,189:89-103.
[24]王山,梁兆光. 炎症反应与心房颤动的关系[J]. 心血管病学进展,2019,40(5):770-773.
[25]Ju HQ,Gocho T,Aguilar M,et al. Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation[J]. Mol Cancer Ther,2015,14(3):788-798.
[26]Zhao H,Wu S,Li H,et al. ROS/KRAS/AMPK signaling contributes to gemcitabine-induced stem-like cell properties in pancreatic cancer[J]. Mol Ther Oncolytics,2019,14:299-312.
[27]Pelicano H,Carney D,Huang P. ROS stress in cancer cells and therapeutic implications[J].Drug Resist Updat,2004,7(2):97-110.
[28]Mihaylova MM,Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism[J].Nat Cell Biol,2011,13(9):1016-1023.
[29]Yeh ETH,Bickford CL. Cardiovascular complications of cancer therapy:incidence, pathogenesis, diagnosis, and management[J]. J Am Coll Cardiol,2009,53(24):2231-2247.
[30]Ewer MS,Ewer SM. Cardiotoxicity of anticancer treatments:what the cardiologist needs to know[J]. Nat Rev Cardiol, 2010,7(10):564-575.
[31]Sawaya H,Sebag IA,Plana JC. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines,taxanes,and trastuzumab[J]. Circ Cardiovasc Imaging, 2012,5(5):596-603.
[32]Bloom MW,Hamo CE,Cardinale D,et al. Cancer therapy-related cardiac dysfunction and heart failure:part 1: definitions, pathophysiology, risk factors, and imaging[J]. Circ Heart Fail,2016,9(1):e002661.
[33]刘元芬,周咏梅. 紫杉醇与吉西他滨联合抗肿瘤作用机制及共载给药系统的研究进展[J]中国新药杂志, 2019,28(9):1081-1086.
[34]von Hoff DD,Ervin T,Arena FP,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med,2013,369(18):1691-1703.
[35]刘成裕,刘广宣. 吉西他滨及其增效剂对胰腺癌细胞作用机制的研究进展[J]. 现代药物与临床,2019,34(1):261-265.
[36]Baranski JD,Chaturvedi RR,Stevens KR,et al. Geometric control of vascular networks to enhance engineered tissue integration and function[J]. Proc Natl Acad Sci USA,2013,110(19):7586-7591.
[37]Matsui H,Morishima I,Numaguchi Y,et al. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats[J]. Life Sci,1999,65(12):1265-1274.
相似文献/References:
[1]祁小青 周蕾.肿瘤治疗所致Ⅰ型心脏损伤的防治[J].心血管病学进展,2020,(7):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
QI Xiaoqing,ZHOU Lei.Prevention and Treatment of TypeCardiac Injury Caused by Cancer Treatment[J].Advances in Cardiovascular Diseases,2020,(9):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
[2]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[3]古力尼尕尔·麦麦提吐尔孙 付真彦.肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展[J].心血管病学进展,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
GULINIGAER·Maimaitituersun,FU Zhenyan.EGFR-TKI and Its Cardiotoxicity in Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(9):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
[4]杨懿 牟云飞 任福强 黄鑫 王园.表皮生长因子受体酪氨酸激酶抑制剂用于非小细胞肺癌术后辅助治疗的心脏毒性回顾性分析[J].心血管病学进展,2022,(8):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
YANG Yi,MU Yunfei,REN Fuqiang,et al.A Retrospective Analysis of EGFR-TKIs-Induced Cardiotoxicity in Postoperative Adjuvant Therapy for Non-Small Cell Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(9):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
[5]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(9):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
[6]王鹏 王鑫 张瑶 张经泽 贺世豪 李瑾.内质网应激在阿霉素心脏毒性中作用的研究进展[J].心血管病学进展,2023,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
WANG Peng,WANG Xin,ZHANG Yao,et al.Role of Endoplasmic Reticulum Stress?n the Cardiotoxicity of Doxorubicin[J].Advances in Cardiovascular Diseases,2023,(9):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
[7]邓悦 周晓阳.免疫检查点抑制剂相关心脏毒性的临床特点及研究进展[J].心血管病学进展,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
DENG YueZHOU Xiaoyang?/html>.Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors[J].Advances in Cardiovascular Diseases,2023,(9):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
[8]李登科 张伟 黄从新.SIRT1介导的信号通路在阿霉素诱导心脏毒性中的作用机制[J].心血管病学进展,2024,(3):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
LI Dengke,ZHANG Wei,HUANG Congxin.The Mechanisms of SIRT1-Mediated Signal Pathway in Doxorubicin-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(9):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
[9]赵 珂 陈晓姝 魏希进 张 娟 刘 杨 卞雨敬 袁 杰.铁死亡的调控机制及其在蒽环类药物心脏毒性中的研究进展[J].心血管病学进展,2024,(3):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]
First Clinical Medical College,Shandong University of Traditional Chinese Medicine,Jinan 0000,et al.Regulatory Mechanism of Ferroptosis and Its Progress in Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(9):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]